Several clinical immunotherapy trials with cytokine-induced killer (CIK) cells have been reported. However， molecular evidence of cell expansion， acquisition of tumor cytotoxicity， and safety of CIK cells is required before putting them to clinical use. Here， we performed dynamic transcriptomic analyses of CIKs generated from primary peripheral blood mononuclear cells exposed to interferon-γ， OKT3， and interleukin-2. CIK mRNAs were extracted and sequenced at days 0， 1， 7， and 14 and subjected to bioinformatics analyses. Using weighted correlation network analysis (WGCNA)， we identified two major gene modules that mediate immune cell activation and mitosis. We found that activation and cytot... More
Several clinical immunotherapy trials with cytokine-induced killer (CIK) cells have been reported. However， molecular evidence of cell expansion， acquisition of tumor cytotoxicity， and safety of CIK cells is required before putting them to clinical use. Here， we performed dynamic transcriptomic analyses of CIKs generated from primary peripheral blood mononuclear cells exposed to interferon-γ， OKT3， and interleukin-2. CIK mRNAs were extracted and sequenced at days 0， 1， 7， and 14 and subjected to bioinformatics analyses. Using weighted correlation network analysis (WGCNA)， we identified two major gene modules that mediate immune cell activation and mitosis. We found that activation and cytotoxicity of CIK cells likely rely on cluster of differentiation 8 (CD8) and its protein partner LCK proto-oncogene， Src family tyrosine kinase (LCK). A time-course series analysis revealed that CIK cells have relatively low immunogenicity because of decreased expression of some self-antigens. Importantly， we identified several crucial activating receptors and auxiliary adhesion receptors expressed on CIK cells that may function as tumor sensors. Interestingly， cytotoxicity-associated genes， including those encoding PRF1， GZMB， FASL， and several cytokines， were up-regulated in mature CIK cells. Most immune-checkpoint molecules and inflammatory tumor-promoting factors were down-regulated in the CIK cells， suggesting efficacy and safety in future clinical trials. Notably， insulin-like growth factor 1 (IGF-1) was highly expressed in CIK cells and may promote cytotoxicity， although it also could facilitate tumorigenesis. The transcriptomic atlas of CIK cells presented here may inform efforts to improve CIK-associated tumor cytotoxicity and safety in clinical trials.
